Corvus Pharmaceuticals (CRVS) said late Wednesday preclinical data highlighting the potential of soquelitinib as a novel approach to modulate tumor immunity was published in npj Drug Discovery, a peer-reviewed journal.
The publication includes an overview of soquelitinib's mechanism of action, suppressing the production of Th2 and Th17 cytokine while sparing Th1 cytokines. The company said this is a novel approach to cancer immunotherapy.
"The data also shows that soquelitinib increases effector function of cytotoxic CD8 positive T cells and leads to an increase in memory T cells with enhanced effector function," the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments